Introduction
Despite recent improvements in surgical and chemotherapeutic approaches, about half of the patients diagnosed with advanced gastric cancer (GC) still die from recurrent disease after curative surgery or distant metastasis.
1,2 Fluoropyrimidine-or platinum-based conventional cytotoxic chemotherapy is still widely used as the first-line treatment of GC. 3 However, nearly all patients develop resistance to these drugs with adverse effects, limiting the efficacy of this approach. 4, 5 The only targeted therapeutic agent, trastuzumab (Roche, Basel, Switzerland), increases survival by only a few months, even in a selected biomarker-positive population. 1 Thus, identification of efficacious therapeutic interventions that sensitize GC cells is required to improve the management of GC patients.
The AT-rich interactive domain 1A (ARID1A) is an ARID family member that encodes a subunit of the Switch/Sucrose nonfermentable chromatin remodeling family.
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lee et al differentiation, proliferation, and DNA repair. 7 Recent genome-wide sequencing studies demonstrated that ARID1A is frequently mutated in ovarian and endometrial cancers, and also in GCs, ranging from 8% to 33%. [8] [9] [10] [11] [12] Genetic alterations in ARID1A in GCs are mostly insertion/deletion mutations, which lead to truncation of ARID1A protein. 10 Loss of ARID1A protein is considered a poor prognostic factor in a variety of cancers, including GC. 13 Growing evidence indicates that loss of ARID1A expression leads to the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, mainly due to AKT phosphorylation. [14] [15] [16] This appears to be true in GCs, as we previously demonstrated in the human GC tissues by immunohistochemistry. 17 If ARID1A-deficient tumor cells depend on constitutive activation of the AKT pathway, it is assumed that tumor cells lacking ARID1A expression may be more vulnerable to the selective AKT pathway inhibitors. 18 In support of this notion, MCF7 breast cancer cells and primary MRC5 cells exhibit significantly increased sensitivity to the AKT inhibitors, MK-2206 and perifosine, as well as the PI3K inhibitor, buparlisib, after ARID1A knockdown. 19 In this study, we demonstrate that loss of ARID1A promotes proliferation of cancer cells by activating the AKT signaling pathway in GC cell lines. The promising preclinical activity of selective AKT pathway inhibitors was demonstrated in ARID1A-deficient GC cells.
Materials and methods cell lines and cell culture
MKN-1, MKN-28, MKN-45, KATO-III, AGS, MKN-74, and NCI-N87 human GC cell lines were purchased from the Korean Cell Line Bank and were maintained in RPMI 1640 (Hyclone, South Lagan, UT, USA) supplemented with 10% fetal bovine serum, 1% penicillin, and streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 .
reagents and antibodies
The following reagents and antibodies were used: GSK690693 (Cell Signalling Technology, Danvers, MA, USA), 5-fluorouracil (5-FU) and cisplatin (both from SigmaAldrich, St Louis, MO, USA), ARID1A, p-AKT, AKT, p-S6, poly-ADP ribose polymerase (1:1,000; Cell Signalling Technology), and β-actin (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Western blot analysis
After treatment with the specified drugs, cells were washed with PBS and lysed in the lysis buffer. Lysates were centrifuged at 13,000 rpm for 20 min at 4°C and then incubated on ice for 20 min. Protein concentration was determined by the Bradford assay (Bio-Rad, Hercules, CA, USA). Equal amounts of protein from each sample were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). The immunoblots were blocked by incubation in 5% skim milk, 25 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.1% Tween 20 for 1 hour at room temperature. The membrane was then incubated with primary antibodies on a shaker overnight at 4°C. Protein detection was performed using the ECL kit (Abclon, Seoul, Korea).
rna interference
ARID1A depletion was done by transfection of MKN-1, MKN-28, and KATO-III cells with SMARTpool: ONTARGETplus ARID1A siRNA (L-017263-00-0005; GE Dharmacon, Lafayette, CO, USA). siRNAs were transfected using DharmaFECT1 (GE Dharmacon). In addition, MKN-1, MKN-28, and KATO-III cells were infected with a lentivirus encoding a nonspecific (NS) scramble shRNA (#1864; Addgene, Cambridge, MA, USA), Mission ARID1A shRNA#2 (NM00615.3-TRCN0000059089; SigmaAldrich), or Mission ARID1A shRNA#3 (NM00615.3-TRCN0000059090; Sigma-Aldrich) using polybrene (EMD Millipore). After infection, cells were selected with puromycin (Sigma-Aldrich) and ARID1A expression levels were checked by Western blot.
cell viability assay
After 48-hour exposure of specified drugs, cells were analyzed using EZ-CYTOX cell viability assay kit (Daeillab Services, Seoul, Korea). Cells were plated in 96-well plates. EZ-CYTOX solution was added to each well of the plates and incubated at 37°C for 1.5-2 hours. The absorbance was measured at 450 nm.
cell apoptosis
To detect synergistic effects of the chemotherapeutic drugs on cell apoptosis, treated cells were analyzed using the fluorescein isothiocyanate-Annexin V apoptosis kit (BD Biosciences, San Jose, CA, USA). The results were analyzed by flow cytometry using an FACSAria III device (BD Biosciences). All the experiments were repeated independently in triplicate. Figure 1A ). Then, we selected MKN-1, MKN-28, and KATO-III and silenced endogenous ARID1A using siRNAs in these cells. The siRNA remained as effective till 48 hours after transfection. ARID1A depletion increased cell proliferation compared to the controls (P,0.001), and it accelerated the phosphorylation of AKT and its downstream S6 proteins in a dose-dependent manner ( Figure 1B-D) .
ARID1A-deficient GC cells are vulnerable to select aKT inhibitors
After transfection with control-siRNA and siARID1A, GC cells were incubated with increasing concentrations (0.01-10 μmol/L) of the AKT inhibitor, GSK690693, for 48 hours, followed by cell viability detection (Figure 2 ). ARID1A-deficient cells were more vulnerable to the AKT inhibitor compared to the controls (P,0.001), even at very low doses. Consistent with this, ARID1A-deficient MKN-45 cells were most sensitive to GSK690693. The IC 50 value of the wild-type (ARID1A-loss) MKN-45 was 0.043, while the IC 50 values of the wild-type (ARID1A-intact) MKN-1, MKN-28, and KATO-III cells were 0.132, 0.084, and 4.521, respectively (P,0.001; Figure 3 ).
aKT inhibition leads to increased apoptosis in ARID1A-deficient cells 
Discussion
We demonstrate that loss of ARID1A induces cellular proliferation by activating the PI3K/AKT signaling pathway. ARID1A-deficient cancer cells were much more vulnerable to the AKT inhibitor, possibly due to the more significant abrogation of p-AKT and its downstream node p-S6 in ARID1A-depleted cancer cells treated with GSK690693. ARID1A knockdown sensitizes MCF7 breast cancer cells and HGC-27/SGC-7901 GC cells to PI3K and AKT inhibition. 19, 20 We confirmed this using different GC cell lines, suggesting that this phenomenon is ubiquitous regardless of cancer types. In addition, combination treatment of AKT inhibitor with conventional chemotherapy had an additive effect in 
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AKT inhibition in ARID1A-deficient gastric cancer ARID1A-knockdown GC cells, which might have clinical utility in the future. The PI3K/AKT pathway is frequently altered in cancers, promoting growth, proliferation, and survival. 21, 22 Targeting its major nodes, such as PI3K or AKT, may represent a key therapeutic opportunity. 21 Since the PI3K/AKT pathway has also been implicated in carcinogenesis and progression of GC, clinical investigations have targeted the PI3K/AKT pathway in patients with GC. 23 However, the clinical efficacy of these inhibitors as monotherapy in particular has, so far, been limited, showing very low response rate. 24 These failures possibly stem from the lack of appropriate patient selection based on a reliable biomarker.
Here, we present ARID1A as a surrogate marker for the activation of AKT pathway and may also anticipate more improved clinical response when patients with ARID1A-negative GC are 
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lee et al treated with AKT inhibitors. Moreover, unlike other protein biomarkers, the expression status of ARID1A in tumor tissue can be clearly distinguished and leaves no concern for interobserver variability in most cases.
17
PI3K/AKT has been implicated for chemotherapy resistance, including resistance for trastuzumab treatment. 25 A clinical investigation revealed that the loss of ARID1A expression was related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
26
ARID1A gene silencing reduced the sensitivity of ovarian clear cell carcinoma to cisplatin. 27 However, in contrast to our expectation, ARID1A-deficient GC cells did not show resistance when treated with conventional chemotherapy, such as 5-FU and cisplatin. Viability of ARID1A-knockdown MKN-28 cells treated with paclitaxel was also similar to that of wild-type cells (data not shown). The exact relationship between ARID1A loss and chemoresistance needs to be investigated further.
The limitations of our study are that only one AKT inhibitor was used and the lack of in vivo experiments. Further assessment of the mechanism of action could shed light on the importance and clinical utility of using AKT inhibitors for treating patients having ARID1A-deficient GC, either singly or in combination.
Conclusion
Loss of ARID1A expression is a surrogate marker for the activation of AKT signaling pathway and also a reliable biomarker to predict the response for the AKT inhibitor. We anticipate that appropriate patient selection based on 
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AKT inhibition in ARID1A-deficient gastric cancer ARID1A expression in the tumor tissue will increase the drug sensitivity for AKT inhibition and improve the clinical outcome. Future mechanistic and in vivo studies should be performed prior to exploring this pathway in clinical trials.
